If you have been reading about lyophilized powder and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-05-29. Where a claim depends on a specific study, the study is described rather than over-claimed.
Once dissolved, the material is considerably less stable than the dry solid. Aqueous solutions are usually kept cold and used within a short window, and neutral or mildly acidic buffers are preferred over strongly alkaline conditions. Freeze-thaw cycles promote aggregation and loss of material to container surfaces, so dividing a batch into single-use aliquots is standard. Adsorption to plastic and glass can lower the measured concentration, meaning solution strength may need rechecking before an experiment.
Identity and purity are established with complementary methods rather than one test. Reverse-phase high-performance liquid chromatography separates the main peak from deletion sequences and oxidized variants, and its area percentage is the usual purity figure. Mass spectrometry confirms the expected molecular mass and can flag truncations or modifications that chromatography alone might miss. Amino acid analysis and peptide mapping add sequence-level confirmation, while residual counter-ion and water content are measured separately.
Proposed mechanisms include interaction with the nitric oxide system, modulation of growth factor signaling, and effects on blood vessel formation. None of these has been established as the primary mode of action, and some proposed pathways rest on indirect measurements. Whether the reported effects depend on a specific receptor has not been determined. Stability in gastric acid, unusual for a peptide of this size, is also reported in animal work, but the reason for it is not firmly established.
Published studies on BPC-157 are dominated by animal models. Commonly used endpoints include healing of surgically induced lesions in the stomach, tendon-to-bone attachment after transection, and recovery from experimentally induced vascular or intestinal damage. Many of these reports come from a small number of research groups, and the peptide is often described as acting across a wide range of tissue types. That breadth is itself a point of discussion, since one molecule influencing many unrelated systems is unusual.
| Property | Value | Notes |
|---|---|---|
| Dry powder storage | -20 °C or below | Desiccated and protected from light |
| Solution storage | 2-8 °C, short term | Aliquot to avoid freeze-thaw cycling |
| Reconstitution solvent | Water or buffered saline | Near-neutral pH is generally preferred |
| Identity confirmation | Mass spectrometry | Matches expected monoisotopic mass |
| Purity assessment | Reverse-phase HPLC | Reported as main-peak area percentage |
Outside laboratory supply channels, the peptide is sold as a research chemical, a category that carries no requirement to demonstrate purity, identity, or freedom from contamination. Because it is not an approved medicine, products labeled BPC-157 sit in a regulatory gap in many countries, and actual content may differ from the label. Sports organizations list it among prohibited substances, so its presence in an athlete's sample can produce a doping finding regardless of how the material was obtained.
BPC-157 is a synthetic peptide of fifteen amino acids, written as GEPPPGKPADDAGLV, whose sequence matches part of a larger protein identified in human gastric juice. That parent protein was described in stomach-secretion research, and the fifteen-residue fragment was named body protection compound, which gives the peptide its common label. Material used in experiments is produced by solid-phase peptide synthesis rather than extracted from tissue. The reported molecular weight is about 1419 daltons, and the chain contains several proline residues, a feature that appears in discussions of its resistance to enzymatic breakdown.
Identity and purity are checked with standard peptide techniques. Reversed-phase high-performance liquid chromatography separates the main peak from closely related impurities and yields a percentage purity. Mass spectrometry confirms that the measured mass matches the theoretical value. Amino acid analysis offers an independent check on overall composition. These analytical methods characterize the material itself and reveal nothing about how it behaves in a living system.
In its common research form the peptide is supplied as a lyophilized powder. It dissolves readily in water and in typical aqueous buffers, which simplifies preparation of working solutions. Laboratories usually prepare small aliquots instead of one large volume. The dry material appears as a white to off-white solid with no distinctive odor. Bulk quantities are typically shipped in sealed vials.
Lyophilized material is generally kept cold, commonly at minus twenty degrees Celsius, and shielded from moisture and light. Solutions are less stable than the dry powder, so repeated freeze-thaw cycles are avoided by splitting the material into single-use portions. Published stability data for this particular peptide are limited, which means suggested hold times should be read as provisional. Long-term refrigeration of reconstituted solutions is not well supported by available evidence.
Direct human evidence is scarce. One trial in ulcerative colitis delivered the compound by enema and produced limited publicly reported results without a clear benefit. The compound is not an approved medicine in most jurisdictions. In many markets it is sold as a research chemical; in others it falls under prescription or controlled categories. Regulators have not confirmed any claimed medical use, and product labels rarely undergo premarket review.
Most published reports describe experiments in rodents rather than in people. These studies examine outcomes in tendons, ligaments, bone, stomach lining, and intestinal tissue. In rat and mouse models, a frequently reported effect is faster healing or reduced damage. Sample sizes are usually small, and a substantial share of the work originates from a small number of research groups. Independent replication is limited, so how far the findings extend to humans remains an open question.
Proposed mechanisms in the literature involve the nitric oxide system, vascular endothelial growth factor signaling, and epidermal growth factor receptor pathways. Some studies report changes in blood vessel formation or in inflammatory mediators, while others describe interactions with nervous tissue. Much of this evidence rests on molecular markers in cultured cells or animal models. Whether the same pathways operate the same way in humans has not been established. Authors therefore tend to describe mechanisms as hypothetical rather than settled.
=== Undigested food remnants === Sometimes undigested food may make an appearance in feces. Common undigested foods found in human feces are seeds, nuts, and corn, mainly because of their high fiber content. Beets may turn feces different hues of red. Artificial food coloring in some processed foods, such as highly colorful packaged breakfast cereals, can cause an unusual coloring of feces if eaten in sufficient quantities. Undigested objects such as seeds can pass through the human digestive system, and later germinate. One result of this is tomato plants growing where treated sewage sludge has been used as fertilizer.
RSNa + R'COCl → R'COSR + NaCl Another common route entails the displacement of halides by the alkali metal salt of a thiocarboxylic acid. (The analogous alkylation of a carboxylate salt is rarely practiced.) For example, thioacetate esters are commonly prepared by alkylation of potassium thioacetate:
== Recognition == From 1953 to 1962, Gross served on the Committee on the Skeletal System for the National Research Council. During that period, from 1956 to 1960, he was appointed Associate Editor of the Journal of Histochemistry and Cytochemistry. In 1956, he was named an Established Investigator for the American Heart Association. Gross's most longstanding post was at the Helen Hay Whitney Foundation at the Scientific Advisory Committee, where he served from 1956 to 1991. In 1959, he received the Ciba Foundation Award for Research Relevant to the Problems of Aging. That same year he was appointed to the Advisory Panel on Molecular Biology at the National Science Foundation, where he served until 1962. That year he served as chairman of the Board of Scientific Counselors at the National Institute of Dental Research. He remained in that position until 1966. In 1963, Gross won the Special Award of the Society of Cosmetic Chemists. That same year he was named Advisory Editor for the Journal of Cosmetic Chemists, where he remained until 1971. From 1965 to 1968 he was Consulting Editor at Developmental Biology. In 1966, he was elected to fellowship in the American Academy of Arts and Sciences. Eight years later he was elected to membership in the National Academy of Sciences. Gross served on the editorial board of the Journal of Biological Chemistry from 1976 to 1981 and Chairman of the Committee on Research, MGH, from 1979 to 1982. He joined the Board of Trustees of the Helen Hay Whitney Foundation in 1985.
It has been indicated that where there was a policy of providing IAP for GBS colonized mothers, the overall risk of EOGBS is 0.3%. Though maternal GBS colonization is the key determinant for EOD, other factors also increase the risk. These factors include onset of labor before 37 weeks of gestation (premature birth), prolonged rupture of membranes (> 18 h before delivery), intra-partum fever (>38 °C, >100.4 °F), amniotic infections (chorioamnionitis), young maternal age, and low levels of GBS anticapsular polysaccharide antibodies in the mother. Nevertheless, most babies who develop EOD are born to GBS colonized mothers without any additional risk factor. A previous sibling with EOD is also an important risk factor for the development of the infection in subsequent deliveries, probably reflecting a lack of GBS polysaccharides protective antibodies in the mother. Heavy GBS vaginal colonization is also associated with a higher risk for EOD. Overall, the case–fatality rates from EOD have declined, from 50% observed in studies from the 1970s to 2 to 10% in recent years, mainly as a consequence of improvements in therapy and management. Fatal neonatal infections by GBS are more frequent among premature infants. GBS LOD affects infants from 7 days to 3 months of age and is more likely to cause bacteremia or meningitis. LOD can be acquired from the mother or from environmental sources. Hearing loss and mental impairment can be long-term sequelae of GBS meningitis.
Pauses a rule issued under the Biden administration to cancel student loans if schools engaged in deceptive recruiting; Caps unsubsidized student loans for graduate students at $20,500 per year and $100,000 lifetime; Caps student loans for students seeking professional degrees, such as medical school or law school, at $50,000 per year and $200,000 lifetime, and eliminates graduate PLUS loans; Establishes a lifetime student loan borrowing limit of $257,000; Restructures income-based repayment programs; and Expands Pell Grants to cover workforce-training programs.
Sources: en.wikipedia.org
Generative adversarial networks (GANs) are a generative modeling technique which consist of two neural networks—the generator and the discriminator—trained simultaneously in a competitive setting. The generator creates synthetic data by transforming random noise into samples that resemble the training dataset. The discriminator is trained to distinguish the authentic data from synthetic data produced by the generator. The two models engage in a minimax game: the generator aims to create increasingly realistic data to "fool" the discriminator, while the discriminator improves its ability to distinguish real from fake data. This continuous training setup enables the generator to produce high-quality and realistic outputs.
== Further reading == Baena-Cagnani CE (2001). "Desloratadine activity in concurrent seasonal allergic rhinitis and asthma". Allergy. 56 Suppl 65: 21–7. doi:10.1111/j.1398-9995.2001.00001.x-i1. PMID 11243501. Devillier P, Roche N, Faisy C (2008). "Clinical pharmacokinetics and pharmacodynamics of desloratadine, fexofenadine and levocetirizine : a comparative review". Clinical Pharmacokinetics. 47 (4): 217–30. doi:10.2165/00003088-200847040-00001. PMID 18336052. Geha RS, Meltzer EO (April 2001). "Desloratadine: A new, nonsedating, oral antihistamine". The Journal of Allergy and Clinical Immunology. 107 (4): 751–62. doi:10.1067/mai.2001.114239. PMID 11295678. Henz BM (2001). "The pharmacologic profile of desloratadine: a review". Allergy. 56 Suppl 65: 7–13. doi:10.1034/j.1398-9995.2001.00101.x. PMID 11243504.
=== Inflating prices fine (2022) === In July 2022, UK antitrust authorities fined Pfizer £63 million for unfairly pricing a drug that aids in controlling epileptic seizures. The Competition and Markets Authority stated that the company and Flynn took advantage of a loophole by de-branding the epilepsy drug Epanutin (phenytoin sodium capsules). This meant the price of the drug was no longer regulated and the companies could raise the price of the drug unchecked. It was stated that over a four-year period, Pfizer had billed Epanutin for around 780% and 1,600% higher than its standard price.
=== National advisory and leadership roles === Eaton was elected to the Institute of Medicine (now the National Academy of Medicine) in 2011 and has led key national scientific committees. He presided over NASEM committees on the health effects of e-cigarettes (2018), dioxin exposure (2004–2006), and engineered nanoscale materials (2008). He led the 2018 cell phone radiation review panel, advised the NIEHS/NTP Director (2023–2024), and chaired the Board of Scientific Counselors (2020–2022) for the National Toxicology Program. He was Chair of the Health Effects Institute Research Committee (2010–2018) and President of the Society of Toxicology (2001–2002) and the Academy of Toxicological Sciences (2025–2026).
=== Novel genes === In general, genes without detectable homologs can be summarized under the term novel genes. These genes can also be called orphan genes, or — more precisely — species-/lineage-specific genes. The term de novo describes a specific subclass of novel genes, namely genes emerging from non-genic sequences. A key caveat is that orphan (taxonomically restricted) genes are heterogeneous in origin and age—lack of detectable homology can reflect multiple processes (including horizontal transfer, transposable element domestication, overprinting, or extreme divergence) and is not, by itself, evidence of de novo origin.
Sources: en.wikipedia.org
NY Mag unfavorably compared the user workflow of agent-based web browsers to Amazon Alexa, which was "software talking to software, not humans talking to software pretending to be humans to use software." The same outlet described web browser agents and computer-use agents as an attempt to "click-farm the entire economy." Agents have been linked to the dead Internet theory due to their ability to both publish and engage with online content. Agents may get stuck in infinite loops. Since many inter-agent protocols are being developed by large technology companies, there are concerns that those companies could use these protocols to benefit themselves. A June 2025 Gartner report accused many projects described as agentic AI of being rebrands of previously released products, terming the phenomenon "agent washing". Researchers have warned about the impact of providing AI agents access to cryptocurrency and smart contracts. During a vibe coding experiment, a coding agent by Replit deleted a production database during a code freeze, "[covered] up bugs and issues by creating fake data [and] fake reports" and responded with false information. A user of Google Antigravity reported that, when the user attempted to use the system to delete cache, the system responded by deleting the user's D hard drive. In July 2025, PauseAI referred OpenAI to the Australian Federal Police, accusing the company of violating Australian laws through ChatGPT agent due to the risk of assisting the development of biological weapons.
== Antibiotic resistance == Studies have shown that L. fermentum has antibiotic resistances. L. fermentum is inherently vancomycin resistant, as are all other Lactobacillaceae with exception of species in the genera Lactobacillus, Holzapfelia and Amylolactobacillus. DNA was isolated from L. fermentum and tested for antibiotic resistance against clinically important agents by using broth dilution tests. Different strains of L. fermentum demonstrated uniform resistance patterns demonstrating resistance to glycopeptide and to tetracycline.
Apamin is an 18 amino acid globular peptide neurotoxin found in apitoxin (bee venom). Dry bee venom consists of 2–3% of apamin. Apamin selectively blocks SK channels, a type of Ca2+-activated K+ channel expressed in the central nervous system. Toxicity is caused by only a few amino acids, in particular cysteine1, lysine4, arginine13, arginine14 and histidine18. These amino acids are involved in the binding of apamin to the Ca2+-activated K+ channel. Due to its specificity for SK channels, apamin is used as a drug in biomedical research to study the electrical properties of SK channels and their role in the afterhyperpolarizations occurring immediately following an action potential.
== Nuclear properties == Technetium-99m is a metastable nuclear isomer, as indicated by the "m" after its mass number 99. This means it is a nuclide in an excited (metastable) state that lasts much longer than is typical. The nucleus will eventually relax (i.e., de-excite) to its ground state through the emission of gamma rays or internal conversion electrons. These decays do not change the number of protons or neutrons, but only give them a lower-energy 'arrangement', which here is the ground state. The excitation energy above the ground state is 142.7 keV, but 99% of the time, it relaxes first to a slightly lower state (140.5 keV) by internal conversion (and the rate of this transition determines the uncertainty in half-life), which decays at once. In total, 99mTc decays about 89% by gamma emission (99mTc → 99Tc + γ) and almost all of the time, this results in a 140.5 keV gamma ray and only rarely in a 142.7 keV (1 in 4,000) as the latter decay, too, is very largely converted. The remaining 11% of decays are completed entirely by conversion and not of diagnostic utility, though still contributing to internal radiation dose. These gammas are the radiations that are picked up by a gamma camera when 99mTc is used as a radioactive tracer for medical imaging. Pure gamma emission is the desirable decay mode for medical imaging because other particles deposit more energy in the patient body (radiation dose) relatively to that in the camera. Metastable isomeric transition is the only nuclear decay mode that approaches pure gamma emission.
Lithium-ion Battery at the Encyclopædia Britannica. Degradation Mechanisms and Lifetime Prediction for Lithium-Ion Batteries, NREL, July 2015. Impact of Temperature Extremes on Large Format Li-ion Batteries for Vehicle Applications, NREL, March 2013.
Sources: en.wikipedia.org
Low temperature slows the chemical reactions, such as oxidation and hydrolysis, that break down a peptide chain. Water and oxygen are the main drivers of degradation, so a cold and dry environment extends usable life. Actual shelf life depends on the batch, the salt form, and the container.
It normally reports the share of the chromatographic signal that belongs to the main peak, not a measure of activity. A high figure means few related substances were detected under the stated method and wavelength. Different laboratories and methods can return different values for the same material.
Retention time alone is weak evidence, because unrelated peptides can elute at similar positions. Amino acid analysis or peptide mapping gives stronger sequence information when a mass spectrometer is unavailable. Most laboratories still treat mass confirmation as the standard step for verifying the correct compound.
It is not authorized as a medicine in the United States or the European Union. Regulatory treatment varies by jurisdiction, and in several places it is handled as a research chemical. Therapeutic claims are not supported by large human trials.